43 min

The big pharma sourcing specialist Molecule to Market: Inside the outsourcing space

    • Life Sciences

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hogan, External Manufacturing Team Lead for the Americas at Bayer Pharmaceuticals.


Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Daniel, covering:


Managing a portfolio of 30-50 CMO partners across OSD, aerosols, topicals and liquids. And why due diligence and careful CMO selection is vital given its 10 x harder to exit a site.

Some of the fundamental differences and similarities between sourcing as a big pharma and a small biotech.

What good and bad relationships look like with an outsourced partner.

The proliferation and availability of vendors in the outsourcing space. And why there is always room for CDMOs/CMOs with novel capabilities.

Timeless advice for CDMOs/CMOs/CPOs in building relationships and revenue with big pharma.


With almost 20 years in the sector, Dan’s technical knowledge encompasses diverse pharmaceutical dosage forms with experience manufacturing and formulating a wide range of products for oral, topical, and parenteral administration. He thrives on contributing to complex products with the potential to cure people of disease, enabling them to lead lives of health and wellness.


Leading a team of experienced engineers responsible for the technology interface between Bayer and Contract Manufacturing Organizations (CMOs), Dan currently manages the manufacturing of a diverse dosage, multimillion-dollar product portfolio while providing guidance on activities such as process optimization, technology transfer from Bayer research and development to CMOs and validation of processes at commercial scale at various CMOs.


Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!


Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.


We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com


 

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hogan, External Manufacturing Team Lead for the Americas at Bayer Pharmaceuticals.


Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Daniel, covering:


Managing a portfolio of 30-50 CMO partners across OSD, aerosols, topicals and liquids. And why due diligence and careful CMO selection is vital given its 10 x harder to exit a site.

Some of the fundamental differences and similarities between sourcing as a big pharma and a small biotech.

What good and bad relationships look like with an outsourced partner.

The proliferation and availability of vendors in the outsourcing space. And why there is always room for CDMOs/CMOs with novel capabilities.

Timeless advice for CDMOs/CMOs/CPOs in building relationships and revenue with big pharma.


With almost 20 years in the sector, Dan’s technical knowledge encompasses diverse pharmaceutical dosage forms with experience manufacturing and formulating a wide range of products for oral, topical, and parenteral administration. He thrives on contributing to complex products with the potential to cure people of disease, enabling them to lead lives of health and wellness.


Leading a team of experienced engineers responsible for the technology interface between Bayer and Contract Manufacturing Organizations (CMOs), Dan currently manages the manufacturing of a diverse dosage, multimillion-dollar product portfolio while providing guidance on activities such as process optimization, technology transfer from Bayer research and development to CMOs and validation of processes at commercial scale at various CMOs.


Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!


Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.


We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com


 

43 min